Safety and exercise tolerance of acute high altitude exposure (3454 m) among patients with coronary artery disease

J-P Schmid, M Noveanu, R Gaillet, G Hellige, A Wahl and H Saner

Heart 2006;92:921-925; originally published online 9 Dec 2005; doi:10.1136/hrt.2005.072520

Updated information and services can be found at: http://heart.bmjournals.com/cgi/content/full/92/7/921

These include:

References
This article cites 25 articles, 15 of which can be accessed free at: http://heart.bmjournals.com/cgi/content/full/92/7/921#BIBL

Rapid responses
You can respond to this article at: http://heart.bmjournals.com/cgi/eletter-submit/92/7/921

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Topic collections
Articles on similar topics can be found in the following collections

- Rehabilitation Medicine (152 articles)
- Ischemic heart disease (1982 articles)
- Sports Medicine (1245 articles)

Notes

To order reprints of this article go to: http://www.bmjournals.com/cgi/reprintform

To subscribe to Heart go to: http://www.bmjournals.com/subscriptions/
Safety and exercise tolerance of acute high altitude exposure (3454 m) among patients with coronary artery disease

J-P Schmid, M Noveanu, R Gailliet, G Hellige, A Wahl, H Saner

Objectives: To assess the safety and cardiopulmonary adaptation to high altitude exposure among patients with coronary artery disease.

Methods: 22 patients (20 men and 2 women), mean age 57 (SD 7) years, underwent a maximal, symptom limited exercise stress test in Bern, Switzerland (540 m) and after a rapid ascent to the Jungfraujoch (3454 m). The study population comprised 15 patients after ST elevation myocardial infarction and 7 after a non-ST elevation myocardial infarction 12 (SD 4) months after the acute event. All patients were revascularised either by percutaneous coronary angioplasty (n = 15) or by coronary artery bypass surgery (n = 7). Ejection fraction was 60 (SD 8%). β blocking agents were withheld for five days before exercise testing.

Results: At 3454 m, peak oxygen uptake decreased by 19% (p < 0.001), maximum work capacity by 15% (p < 0.001) and exercise time by 16% (p < 0.001); heart rate, ventilation and lactate were significantly higher at every level of exercise, except at maximum exertion. No ECG signs of myocardial ischaemia or significant arrhythmias were noted.

Conclusions: Although oxygen demand and lactate concentrations are higher during exercise at high altitude, a rapid ascent and submaximal exercise can be considered safe at an altitude of 3454 m for low risk patients six months after revascularisation for an acute coronary event and a normal exercise stress test at low altitude.

Leisure time activities at moderate or high altitude are very popular in mountain areas. An increasing number of recreational facilities with easy access even to high altitudes allows a broad public, including sedentary people, elderly people and patients with various diseases, to be exposed to altitudes beyond 3000 m. In patients with coronary artery disease (CAD), the safety of high altitude exposure has been of concern for a long time. Recommendations to date for exposure to or activities at high altitude in this group of patients are based on empirical rather than scientific data, since only a few reports on high altitude exposure with a very limited number of cardiac patients have been published.1–5

The reduction in the inspired oxygen pressure with increasing altitude leads to several important circulatory changes. These changes lead to an increase in cardiac work and cardiac oxygen consumption,6 which may put cardiac patients at risk, raising concern about the safety of high altitude exposure. In patients with CAD, Wyss et al7 observed a significant decrease in exercise induced coronary flow reserve during inhalation of a hypoxic gas mixture corresponding to an altitude of 2500 m compared with baseline measurements at 450 m. This may indicate that compensatory mechanisms that suffice at low altitude may be exhausted even at moderate altitudes in patients with CAD.

Therefore, we studied cardiopulmonary adaptation to exercise and safety of a rapid but realistic touristic ascent to an altitude of 3454 m, which corresponds to the altitude of the highest located tourist attraction in the Swiss alpine region with an easy access by mountain cogwheel railway (Jungfraujoch, Bernese Oberland), visited by > 500 000 people a year.

**METHODS**

**Study population**

The study population comprised 22 patients (two women, 20 men), with a mean age of 57 (SD 7) years and a body mass index of 26 (SD 4) kg/m². All patients had a history of an acute coronary event, which was an ST elevation myocardial infarction in 15 and a non-ST elevation myocardial infarction in seven patients. During the acute event, mean peak creatine kinase concentration was 65 (SD 91) μg/l, peak troponin I was 124 (SD 239) μg/l and ejection fraction was 58 (SD 11)%.

Six patients had three vessel disease, six patients had two vessel disease and 10 patients had one vessel disease. Fifteen patients were treated by percutaneous coronary angioplasty and seven patients by coronary artery bypass grafting. Three vessels with a stenosis < 30% and three vessels with a stenosis < 50% were not revascularised. The culprit lesion was the left anterior descending artery in seven, the circumflex artery in five and the right coronary artery in 10 patients.

After the acute event, all patients participated in an 8–12 week ambulatory rehabilitation programme. Twenty consecutive patients willing to participate were recruited 6–18 months after the acute event (mean 12 (SD 4) months).

At study entry, left ventricular systolic function, measured by echocardiography, was normal with an ejection fraction of 60 (SD 8)% and B-type natriuretic peptide of 50.1 (SD 62.1) pg/ml.

Exclusion criteria were age > 70 years, left ventricular ejection fraction < 45%, an abnormal stress test (chest pain or significant ST segment depression), uncontrolled arterial hypertension (> 160/95 mm Hg at rest), peripheral artery occlusion (> IIb according to the Fontaine classification), functionally relevant valvular disease or significant lung disease (maximum vital capacity or forced expiratory volume in one second < 70% of predicted value).

**Study protocol**

After an initial stress test for screening, all patients underwent a symptom limited cardiopulmonary exercise stress test at our cardiovascular centre (540 m). β blockers were stopped five days before the test for the whole study period. Within
less than three weeks after the first cardiopulmonary exercise stress test, patients started their excursion to the Jungfraujoch at 0700 and reached the altitude of 3454 m by public transportation at 1030. The stay at the Jungfraujoch lasted 4 h and included a regular sightseeing programme and a light meal. The cardiopulmonary exercise stress test was performed indoors in a conference room at the tourist complex between 1–3 h after arrival at this altitude.

The patients were informed about the experimental procedures and possible risks related to the present study and provided informed consent. The local ethics committee reviewed and approved the study protocol.

**Exercise testing**

Cardiopulmonary exercise stress testing with breath by breath gas exchange measurements was performed on a computer-controlled, rotational, speed-independent bicycle ergometer (Cardiovit CT-200 Ergo-Spiro; Schiller AG, Baar, Switzerland). Gases were calibrated each day taking into account the ambient barometric pressure (494 mm Hg). The flow sensor was calibrated before each test. A 12 lead ECG was recorded continuously. Each test consisted of a baseline gas exchange measurement at rest during 1 min, a 3 min reference phase during which patients cycled without a workload and a test phase with a 15 W/min ramp protocol. The following parameters were measured every 2 min: blood pressure, heart rate, subjective rating of perceived exertion (Borg scale) for dyspnoea and muscle fatigue, and lactate concentration (capillary blood samples from the earlobe; Lactate Pro; Arkray Inc, Kyoto, Japan). Gas exchange parameters were VO\(_2\), carbon dioxide output, tidal volume and breathing rate. From these data, minute ventilation and respiratory exchange ratio (ratio of carbon dioxide output to VO\(_2\)) were calculated. Peak VO\(_2\) was defined as the highest VO\(_2\) achieved during the last 30 s of peak exercise. The anaerobic threshold was defined by three criteria: the point after which the respiratory gas exchange ratio becomes 1.0, the V slope method and the point at which the ventilatory equivalent for oxygen (ratio of minute ventilation to VO\(_2\)) and end tidal oxygen pressure was minimal, followed by a steady increase.

**Statistical analysis**

All data are expressed as mean (SD). The Wilcoxon signed ranks test was used to calculate p values for comparison of the means. A value of p < 0.05 was considered significant. Data were analysed with SPSS software V.10.0 (SPSS Inc, Chicago, Illinois, USA).

**RESULTS**

Figure 1 and table 1 show the results for heart rate, blood pressure, ventilation, VO\(_2\), subjective rating of perceived exertion and lactate concentration with cardiopulmonary exercise testing at 540 m and 3454 m.

**Heart rate**

At 3454 m, heart rate at rest was increased by 19% compared with that at low altitude (67 (9) vs 83 (13) beats/min, p = 0.001). For every stage of exercise, heart rate was significantly higher at high altitude, except for peak heart rate at maximum effort. At 3454 m, peak heart rate was significantly lower than at 540 m (159 (11) vs 163 (11), p = 0.021).

**Blood pressure**

There was no significant difference in systolic and diastolic blood pressures between 3454 m and 540 m at rest and at maximal exercise. During the other stages, systolic blood...
pressure was significantly higher at high altitude, whereas diastolic blood pressure did not differ significantly.

**Ventilation**
At rest and at peak exercise, ventilation did not differ significantly at high and low altitude. During the test, ventilation was significantly increased at high altitude at all stages.

**Oxygen uptake**
VO₂ increased equally during submaximal exercise at both altitudes. At 3454 m, VO₂ increased less steeply with increasing work load after 6 min at high altitude and at exhaustion peak VO₂ was significantly lower (22.9 ± 3.9) vs 28.3 ± 4.4 ml/kg/min, p < 0.001). Mean peak VO₂ at low altitude corresponded to 96% of the predicted value (63–123%).

**Subjective rating of perceived exertion (Borg scale)**
Perceived dyspnoea was significantly higher at all stages of exercise, whereas perceived leg fatigue was significantly different only up to 6 min of exercise.

**Lactate**
At every stage, lactate concentrations were higher at 3454 m, except for the maximum value. Whereas at the beginning of exercise differences were only marginal, the values diverged clearly after 4 min. At maximal exercise, lactate concentrations were 7.1 (1.8) at 540 m and 6.9 (1.5) mmol/l at 3454 m (p = 0.715).

Figure 2 shows the results of cardiopulmonary exercise testing in regard to exercise capacity, VO₂ and exercise time. At exhaustion, maximum power output decreased from 189 to 160 W (−15%, p < 0.001), peak VO₂ decreased from 28.3 to 22.9 ml/kg/min (−19%, p < 0.001) and exercise duration decreased from 644 to 538 s (−16%, p < 0.001).

All patients tolerated the rapid ascent from the plain up to 3454 m and the 4 h stay without complications. None of the cardiopulmonary stress tests had to be stopped prematurely. No evidence of stress induced ischaemia or of significant arrhythmias was noted during the stress test and recovery.

**DISCUSSION**

**Study findings**
To our knowledge, this is the first study of the safety of and cardiopulmonary response to exercise among patients after a myocardial infarction at an altitude of 3454 m. For this reason we selected a patient group at very low risk (condition after coronary revascularisation, normal left ventricular function and no signs of ischaemia during an exercise test at low altitude).

A rapid ascent and a 4 h stay in a real life tourist setting were both well tolerated, and no ischaemia or significant arrhythmia occurred during the stress test. To eliminate the influence of β blockers on the physiological adaptation to high altitude, this drug was stopped at least five days before the first exercise test. This actually adds further value to the safety of the study, since the absence of this drug imposed a higher stress on the cardiovascular system during exercise testing.

It is important to note that the data do not apply to patients at a higher risk than that of the population studied. In particular, patients with reduced left ventricular function, with incomplete revascularisation or less than six months after an acute coronary event constitute a different risk population and such patients may be in danger when exposed to such an altitude. This is especially the case for patients presenting symptoms of heart failure. Furthermore,
our study was performed inside a building at room temperature, without exposure to extreme weather conditions. Prolonged outdoor physical activity, with low temperatures or hazardous weather conditions, would impose additional physical stress on such patients. We think that the result of this study will, however, allow a considerable number of patients to be exposed to the higher altitudes to which they had been discouraged to travel.

Risk of high altitude exposure in patients with CAD

For patients with stable CAD, there is concern that exposure to high altitude may elicit ischaemia, increase the risk of arrhythmias or provoke an acute coronary event.

In this study, at submaximal exercise, the rate–pressure product was significantly higher at high altitude at every specific power output stage, due to a higher heart rate and a higher systolic blood pressure, thus imposing a greatly increased myocardial oxygen demand. In addition, sympathetic activation associated with hypoxia can cause coronary vasoconstriction in regions with abnormal endothelial vasomotor control and further compromise myocardial oxygen delivery. Even though our patients were revascularised, some coronary artery stenoses remained (three vessels with a stenosis <30% and three vessels with a stenosis <50%) that were not revascularised, but none of these caused symptoms or abnormalities on the ECG.

The possibility of an increased risk of high grade ventricular arrhythmias is of great concern. The absence of any arrhythmic event with maximal sympathetic activation during maximal exercise stress testing in combination with increased lactic acid concentrations in our patients can be regarded as reassuring. That our patients had normal or only slightly reduced left ventricular function and were fully revascularised, however, must be kept in mind.

Exercise is also known to be associated with an increased risk of myocardial infarction, particularly after heavy exertion. Levine et al. reported from a study with a similar design the occurrence of myocardial infarction in a patient after an exercise stress test at an altitude of 2500 m. Whether high altitude adds to the risk of plaque rupture during exercise is unknown. Changes in inflammatory activation, platelet aggregability and fibrinolytic activity, increased blood pressure and shear forces, changes in the arterial tone and twisting of the arteries during exercise and the role of a haemostatic imbalance as a trigger of acute cardiac events have been discussed as promoters of plaque rupture. We do not expect that high altitude would have a major influence on these triggering mechanisms. In contrast, regular physical activity has been shown to protect against plaque rupture and therefore a history of regular physical activity may be a good predictor of an uneventful stay at high altitude.

Blood pressure, heart rate and ventilatory response to high altitude

Systemic blood pressure increases in response to hypoxia during the early stages of altitude adaptation. Our patients, some of them with treated hypertension, did not have significantly higher resting systolic blood pressures at high altitude. During exercise, however, their systolic pressure response was significantly increased during all stages, except at the maximum. The enhanced blood pressure response is attributed to a higher excitability of arterial chemoreceptors and a reactive increase of the sympathetic nervous tone. Adequate blood pressure control seems therefore important for high altitude exposure tolerance and safety.

At high altitude, submaximal heart rate and cardiac output can rise as much as 50% above sea level values, whereas the heart’s stroke volume remains unchanged. This increase of submaximal exercise blood flow to compensate arterial desaturation was also observed in our study population. At 3454 m, heart rate at rest was 19% higher than at 540 m and remained significantly higher except at maximum effort, which was even significantly lower (159 (11) v 163 (11) beats/min, p = 0.021). This effect of hypoxia on peak heart rate has been a matter of debate for a long time. In a review of several studies on maximum heart rate after acute hypoxic exposure, Lundby et al. have highlighted a possible influence of high altitude on peak heart rate. They determined peak heart rate at increasing simulated high altitudes in a dose–response study of healthy young men, showing that peak heart rate decreases with increasing severity of acute hypoxia in a linear manner up to 6300 m. The heart rate behaviour of our patients with CAD was similar to that of the healthy subjects in the study of Lundby et al. and endorses their findings. As a consequence of a decreased peak heart rate in a hypoxic environment, the maximal cardiac output is also reduced, leading to a reduction in maximum oxygen delivery to the working muscles. Below 3100 m, the reduction of peak VO₂ is primarily caused by a decrease in arterial oxygen saturation, whereas at higher altitudes, a reduction of cardiac output is likely to contribute to the limitation of maximum VO₂ as well. The decrease in peak heart rate seems to be reinforced after days at high altitude and therefore also depends on duration of hypoxic exposure.

Hyperventilation due to reduced arterial oxygen pressure is the most important and most obvious immediate response to high altitude exposure. Arrival at altitudes ≥ 2300 m initiates rapid physiological adjustments to compensate for the “thinner” air with reduction in arterial oxygen pressure.
For any given energy expenditure, ventilation increases proportionately with altitude.28 At the same time, due to a shift upwards and to the left of the relationship between lactate and workload,29 lactate concentrations at high altitude are higher at each stage of exercise, which also contributes to exercise hyperventilation.

**Impact of high altitude on maximum VO₂**

While the atmospheric gas composition of oxygen (20.9%), nitrogen (78%) and inert gases (1.1%) remains the same, the progressive decrease in atmospheric pressure during the ascent (from 760 mm Hg at sea level to 697 mm Hg at 540 m and 494 mm Hg at 3454 m) decreases the ambient partial pressure of oxygen (from 159 mm Hg at sea level to 150 mm Hg at 540 m and 104 mm Hg at 3454 m). The mechanisms compensating for this reduced oxygen supply in a single breath can maintain sufficient oxygen delivery to the peripheral tissues at submaximal effort independently of elevation.29 This was also observed in our patients, who during the first 6 min of exercise had the same VO₂ at 540 m and 3454 m. Thereafter, VO₂ at high altitude began to be restricted and at exhaustion peak VO₂ was 19% lower than at low altitude.

Compared with sea level, small declines in peak VO₂ have been described at an altitude as low as 589 m. Thereafter, arterial desaturation causes peak VO₂ of healthy men and women to decrease at a rate of 7–9% per 1000 m altitude up to an altitude of 6300 m, where aerobic capacity declines at an even more rapid, non-linear rate.27 With a decrease of peak VO₂ of 6.3% per 1000 m difference in altitude, the reduction of VO₂ in our patients with CAD was even lower than the expected rate for normal people.

**Study limitations**

The study population consisted only of patients with revascularised stable CAD without a relevant reduction of left ventricular function and a normal exercise stress test at low altitude. Furthermore, the environment during exercise testing was well controlled and activity was strenuous only during the exercise stress test. Under outdoor environmental conditions and sustained physical activity at this altitude, the study might have led to different results. Therefore, advice given to patients in regard to high altitude exposure should be restricted to the patients represented and to the activity undertaken in our study.

**Conclusion**

Submaximal exercise at high altitude imposes a higher myocardial oxygen demand, ventilatory response and lactate concentrations on patients with CAD than at low altitude. Adaptation to acute high altitude exposure and impact on exercise capacity and VO₂ were the same as described for healthy subjects.

On the basis of our data, patients corresponding to our study population can be allowed exposure to an altitude up to 3454 m for a tourist trip six months after an acute coronary event, provided that a stress test with an appropriate rate-pressure product (at least 25 000 mm Hg · beats/min) is normal and left ventricular function is not compromised. Physical activity at a submaximal level for 3–4 h as in our study can be safely done and a short maximal effort during this time turned out to be safe. If patients want to hike for several hours or if they are going to be exposed to wind, rain, snow or cold, normal exercise capacity should be required (≥ 100% of the predicted value) and patients should be accustomed to regular strenuous physical activities to minimise the risk of incidents.